severe autoimmune disease treatment
7% Survival Gain Vs Standard Chronic Disease Management
The new biopsy-driven approach delivers a 7% survival gain versus standard chronic disease management. By analysing inflamed tissue at the cellular level, doctors can match patients to the most effective biologic rather than guessing. This shift promises quicker remissions, fewer hospital trips and a clearer path for insurers. Medical Disclaimer: